Skip to content

Drug interactions

Conjugated estrogens + Fondaparinux

Severity: Major

Conjugated estrogens and Fondaparinux: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Conjugated estrogens raise thromboembolic risk and can counteract the protective purpose of fondaparinux. This is most relevant in patients being treated for an existing clot.

What this interaction means in plain words

Conjugated estrogens and Fondaparinux can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Evidence level: Moderate

Why it happens

Pharmacodynamic opposition: estrogen-mediated prothrombotic effects versus factor Xa inhibition.

What to do

Avoid estrogen therapy in active thrombosis and use a non-hormonal alternative. Reassess VTE risk if therapy continues.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Conjugated estrogens and Fondaparinux, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Conjugated estrogens with Fondaparinux?

MediHelp rates the interaction as major. Conjugated estrogens and Fondaparinux can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Conjugated estrogens raise thromboembolic risk and can counteract the protective purpose of fondaparinux. This is most relevant in patients being treated for an existing clot.

How serious is the interaction between Conjugated estrogens and Fondaparinux?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid estrogen therapy in active thrombosis and use a non-hormonal alternative. Reassess VTE risk if therapy continues.

What other medicines interact with Fondaparinux?

MediHelp also lists interactions of Fondaparinux with, for example, Defibrotide, Ketorolac, Abciximab. The full list is on the Fondaparinux page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in